Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
MMWR. Morbidity and Mortality Weekly Report · 2023
DOI: 10.15585/mmwr.mm7251a2 ↗Kurz gefasst
Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, 2023. Verfasst von Patrick R Harrington und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: RNA, Viral, COVID-19. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients [EPIC-SR]) were analyzed to investigate the role of nirmatrelvir/ritonavir treatment in COVID-19 rebound. Rates of rebound of SARS-CoV-2 RNA shedding, identified based on an increase in nasopharyngeal viral RNA levels from day 5 (end-of-treatment) to day 10 or day 14, were similar between nirmatrelvir/ritonavir and placebo recipients. Among subjects with a virologic response through day 5, viral RNA rebound occurred in 6.4%-8.4% of nirmatrelvir/ritonavir recipients and 5.9%-6.5% of placebo recipients across EPIC-HR and the 2021/pre-Omicron and 2022/Omicron enrollment periods of EPIC-SR. Viral RNA rebound after nirmatrelvir/ritonavir treatment was not associated with COVID-19-related hospitalization or death. Data from randomized trials demonstrated that SARS-CoV-2 rebound can occur with or without antiviral treatment, supporting the Food and Drug Administration's determination of safety and efficacy of nirmatrelvir/ritonavir in eligible patients at high risk for severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Harrington, P. R., Cong, J., Troy, S. B., Rawson, J. M. O., O'Rear, J. J., Valappil, T. I., McGarry Connelly, S., Farley, J., & Birnkrant, D. (2023). Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7251a2
Vancouver
Harrington PR, Cong J, Troy SB, Rawson JMO, O'Rear JJ, Valappil TI, et al. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022. MMWR. Morbidity and Mortality Weekly Report. 2023. doi:10.15585/mmwr.mm7251a2
BibTeX
@article{Harrington2023,
author = {Harrington, Patrick R and Cong, Jie and Troy, Stephanie B and Rawson, Jonathan M O and O'Rear, Julian J and Valappil, Thamban Illath and McGarry Connelly, Sarah and Farley, John and Birnkrant, Debra},
title = {Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022},
journal = {MMWR. Morbidity and Mortality Weekly Report},
year = {2023},
doi = {10.15585/mmwr.mm7251a2}
}
EUVIMED